Hopp til innhold
NHI.no
Annonse

Nyrekreft, nyrecellekreft: Årsak

Innhold i artikkelen

Årsaken er ukjent foruten hos en liten andel på to til tre prosent som skyldes sjeldne arvelige syndromer, først og fremst en tilstand kalt von Hippel-Lindaus syndrom.

Røyking, overvekt, høyt blodtrykk, eksponering for trikloretylen, alvorlig nyresvikt er risikofaktorer. Det skilles mellom en rekke ulike typer nyrecellekreft avhengig av hvilken celletype svulsten består av, hvor den er lokalisert og hvordan den vokser. I sju av ti tilfeller dreier det seg om en type kalt klarcellet nyrecellekreft.

Annonse

Vil du vite mer

Dette dokumentet er basert på det profesjonelle dokumentet Nyrekreft . Referanselisten for dette dokumentet vises nedenfor

  1. Nyrekreft – handlingsprogram, Nasjonal faglig retningslinje Helsedirektoratet 2024. www.helsedirektoratet.no
  2. Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment, and follow-up. Ann Oncol. 2019 May;30(5):706-20. PMID: 30788497 PubMed
  3. Amin MB, Edge S, Green F, et al. AJCC cancer staging manual. 8th ed. (2017). Cham, Switzerland: Springer International; 2017.
  4. Kreftregisteret. Cancer in Norway 2024. Oslo: Kreftregisteret, 2025, www.kreftregisteret.no. www.fhi.no
  5. Maher ER. Hereditary renal cell carcinoma syndromes: diagnosis, surveillance and management. World J Urol. 2018; 36:1891-8. PMID: 29680948 PubMed
  6. Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J Clin Oncol 2004; 22: 4991-5004. PubMed
  7. Haas NB, Nathanson KL. Hereditary kidney cancer syndromes. Adv Chronic Kidney Dis. 2014;21(1):81–90. PMID: 24359990 PubMed
  8. Peyromaure M, Misrai V, Thiounn N, et al. Chromophobe renal cell carcinoma: analysis of 61 cases. Cancer 2004; 100: 1406-10. PubMed
  9. Cumberbatch MG, Rota M, Catto JW, La Vecchia C . The Role of Tobacco Smoke in Bladder and Kidney Carcinogenesis: A Comparison of Exposures and Meta-analysis of Incidence and Mortality Risks.. Eur Urol 2016; 70: 458. pmid:26149669 PubMed
  10. Capitano U, Bensalah K, Bex A, et al. Epidemiology of renal cell carcinoma. Eur Urol 2019; 75: 74-84. pmid:30243799 PubMed
  11. Alanee S, Clemons J, Zahnd W, Sadowski D, Dynda D. Trichloroethylene is associated with kidney cancer mortality: a population-based analysis. Anticancer Res. 2015;35(7):4009–4013. PMID: 26124349. PubMed
  12. Kompotiatis P, Thongprayoon C, Manohar S, et al. Association between urologic malignancies and end-stage renal disease: A meta-analysis. Nephrology (Carlton). 2019; 24: 65-73. PMID: 29236344 PubMed
  13. Campbell S, Uzzo RG, Allaf ME, et al. Renal mass and localized renal cancer: AUA guideline. J Urol. 2017 Sep;198(3):520-9. PMID: 28479239 PubMed
  14. Ouzaid I, Capitanio U, Staehler M, et al. Surgical metastasectomy in renal cell carcinoma: a systematic review. Eur Urol Oncol. 2019 Mar;2(2):141-9. PMID: 31017089 PubMed
  15. Powles T, Albiges L, Bex A et al.: ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma. Ann Oncol. 2021 Dec;32(12):1511-1519. Epub 2021 Sep 28. PMID: 34597799.
  16. Powles T; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Recent eUpdate to the ESMO Clinical Practice Guidelines on renal cell carcinoma on cabozantinib and nivolumab for first-line clear cell renal cancer: Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021 Mar;32(3):422-423. Epub 2020 Nov 30. PMID: 33271289 PubMed
  17. Pessoa RR, Kim S. Renal cell carcinoma. BMJ Best Practice, last reviewed Aug 2022. bestpractice.bmj.com
  18. Motzer RJ, et al. Kidney cancer, version 2. 2017. NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2017;15(6):804–834.PMID: 28596261 PubMed
Annonse
Annonse